The COVID19 Pandemic Response Proves Value of Open Science
Subject: COVID19 and Open Science Discoveries and Developments COVID19, the novel “Coronavirus Disease 2019”, has proven the value proposition “open science” and Open Therapeutics’ free…
PrePrints
Open Therapeutics Founder/Chair, Jason E. Barkeloo, to attend 2020 Asian Financial Forum, Hong Kong Convention and Exhibition Centre, January 13-14, 2020, Hong Kong SAR
Jason E. Barkeloo will attend invitation-only blockchain open science meetings, which will include meeting ultra high networth investors. These meetings are inline with Open Therapeutics…
Merits of Open Access Surpass Challenges
Uncertainty among researchers and stakeholders still prevails over the merits of open access to scientific research. Among the popular criticisms is that payment by authors…
Preprints Could Be an Incentive for Open Collaboration Among Scientific Researchers
The recent threat of severe cutbacks to the NIH, which could still occur, was unnerving to scientific researchers. This makes the best case for opening…
